Co-administration of MTX with Folic Acid on the same day did not reduce efficacy compared to FA application one day after MTX. (based on AIA was induced in female Lewis rats) https://t.co/WBT5BOBPqz https://t.co/bP6O24kgXy

• https://bit.ly/3EL8Z3g

No Special Heart Risk With JAK Inhibitors, Study Finds Patients taking JAK inhibitors for RA experienced similar cardiovascular outcomes as those using the TNF blocker adalimumab (Humira), analysis of French national registry data indicated. https://t.co/Ai3xTPcoO8 https://t.co/TuMaQMWepj

• https://bit.ly/3rYMaBu

Arthritis Clinical Trials Comparison Grid https://t.co/BEvMKU1WEE https://t.co/2TpxMbWE7h

• https://bit.ly/3CA5bis

An incredible opportunity for a free Rheumatology Review course hosted by the Pakistan Rheumatology Society -Event is virtual and registration is free -Course starts tomorrow 10/16 at 1:30 PM Pakistan time (5:30 AM ET) See below for details👇🏼👇🏼👇🏼 https://t.co/tHeFwRZHcG

• https://twitter.com/paedmskglobal/status/1581368051148017664

Sjogrens - Dx tips, myths & mistakes: • SS not rare; affects 1 in 400 • 95% female, but SS is more severe in men • African Americans have a severe systemic phenotype • Asians report dryness Sxs • Smoking & alcohol intake often avoided by SS pts https://t.co/f4C0eYv9Ee https://t.co/OOEXfH6jQs

• https://bit.ly/3exdwLN

Biomedical researchers are at their most creative/innovative EARLY in their career. Study based on 5.6 million papers (1980 to 2009). While least innovative drop out early; in the remaining, innovativeness tends to decline over their career.https://t.co/jXxkEKnl8o https://t.co/mGPokRjkaP

• https://bit.ly/3MwcmwN

Intravenous Immune Globulin in Dermatomyositis Few drugs have been studied well in the treatment of dermatomyositis (DM) and only recently has intravenous immune globulin (IVIG) been granted FDA approval for the treatment of DM, based on this trial. https://t.co/8QeEzX8Eqm https://t.co/hUVLUQJjN6

• https://bit.ly/3Vs2ZCi

In this week's special podcast, Dr. Jack Cush offers a primer on rheumatology clinical trials, answering the question: should you be involved in research and clinical trials in rheumatology? https://t.co/bnf9RyGJWV https://t.co/Md2TPN70hQ

• https://bit.ly/3S5venw

Rheumatology Salaries and Career Choices A recent Doximity report shows how rheumatology salaries increase by years in practice. Rheumatologists tend to earn their highest salaries after gaining 30-39 years of experience. https://t.co/wxWQruIlu9 https://t.co/gUsIffoHn6

• https://bit.ly/3MwyCqi

Popular Post: 2022 New ACR Guidance on Glucocorticoid-Induced Osteoporosis (GIOP) The ACR has updated this guideline and includes recommendations on abaloparatide (PTHrP) and romosozumab, which are newly available since the ACR’s 2017 GIOP guideline. https://t.co/1LEtUvjNUG https://t.co/IYaJzZmg39

• https://bit.ly/3yIHAuP

ACR Announces 2022 Award Recipients The ACR and the ARP proudly recognizes the recipients of its 2022 Master of the ACR and ARP designations, ACR Awards of Distinction, and ARP Awards of Merit and Appreciation. https://t.co/sB3IfvFBJD https://t.co/w8J4qFPvpF

• https://bit.ly/3SZZEZq

Do you renal Bx your #SLE pts? Study of 277 SLE pts w/ US-guided percutaneous renal bx showed bleeding complications post biopsy to be 19.9% (minor 13%; major 7%); risk higher w/ thrombocytopenia (OR 7.12)low eGFR (OR 3.5) https://t.co/kYieyYTUuT https://t.co/ZGobCIcW6v

• https://bit.ly/3TemlsH

EMA CHMP issued a positive opinion on the safety of Filgotinib, a selective JAK1 inhibitor, based on testicular safety data from the MANTA & MANTA-RAy studies. Gilead withdrew filgotinib from US market w/ FDA concerns on testicular safety in 12/20 https://t.co/EawqOGZEZe https://t.co/Bcp6rOReCR

• https://wb.md/3ClfCGo